| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR150 |
| Uniprot No | P11258 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-110aa |
| 氨基酸序列 | MDGTLFPGDDDLAIPATEFFSTKAAKKPEAKREAIVKADEDDNEETLKQRLTNLEKKITNVTTKFEQIEKCCKRNDEVLFRLENHAETLRAAMISLAKKIDVQTGRRPYE |
| 预测分子量 | 17.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR150重组蛋白的假设性参考文献示例(注：以下内容为演示格式，非真实文献，实际研究中请通过学术数据库核实)：
---
1. **文献名称**: *Structural and functional characterization of VACWR150 recombinant protein in Vaccinia virus*
**作者**: Smith, J., et al.
**摘要**: 本研究通过重组表达技术纯化了痘苗病毒WR株的VACWR150蛋白，分析了其三维结构及与宿主细胞膜的相互作用，揭示了该蛋白在病毒组装过程中的关键作用。
2. **文献名称**: *VACWR150 as a novel immune modulator: Insights from in vitro studies*
**作者**: Li, X., & Wang, H.
**摘要**: 利用大肠杆菌表达系统获得高纯度VACWR150重组蛋白，实验表明其能够抑制TLR信号通路，提示其在调节宿主先天免疫反应中的潜在功能。
3. **文献名称**: *Expression optimization and purification of recombinant VACWR150 for vaccine development*
**作者**: Garcia, R., et al.
**摘要**: 通过优化密码子选择和培养条件，实现了VACWR150在哺乳动物细胞中的高效表达，为基于该蛋白的亚单位疫苗研发提供了技术基础。
4. **文献名称**: *Comparative analysis of VACWR150 homologs in poxviruses*
**作者**: Kim, S., et al.
**摘要**: 对多种痘病毒中VACWR150同源蛋白的序列及功能进行比对，发现其高度保守的抗原表位，可能作为广谱抗病毒药物的靶点。
---
**注意**：以上文献为虚构示例，实际研究中请通过PubMed、Web of Science等平台检索真实文献。若需具体论文，建议以“Vaccinia virus WR150”、“VACV recombinant protein”等关键词搜索。
**Background of VACWR150 Recombinant Protein**
VACWR150 is a recombinant protein derived from the vaccinia virus (VACV), a member of the *Poxviridae* family. VACV has been extensively studied as a model for understanding poxvirus biology and as a platform for vaccine development, notably in the eradication of smallpox. The VACWR150 gene encodes a viral protein implicated in modulating host immune responses, a common strategy employed by poxviruses to evade antiviral defenses.
The recombinant VACWR150 protein is typically produced using heterologous expression systems, such as *E. coli* or mammalian cell cultures, followed by purification to ensure high specificity and functionality. Its molecular weight and structural features are consistent with other poxviral proteins involved in host-pathogen interactions, including potential roles in binding host cell components or interfering with signaling pathways.
Research on VACWR150 focuses on its immunomodulatory properties. Studies suggest it may interact with host proteins to suppress innate immune pathways, such as NF-κB or interferon signaling, thereby facilitating viral replication. Additionally, recombinant VACWR150 serves as a tool for investigating poxvirus pathogenesis and developing countermeasures, including vaccines or therapeutics targeting immune evasion mechanisms. Its application extends to immunological assays, antibody production, and as a candidate antigen in subunit vaccine design.
Characterization of VACWR150 contributes to broader virology and immunology fields, offering insights into viral immune evasion tactics and informing strategies to combat poxviral infections or engineer safer viral vectors for gene therapy and oncolytic treatments.
×
